2026 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU 2026)

San Francisco, California, US 26 February 2026 - 28 February 2026

Bladder-sparing regimen for MIBC shows promising antitumour activity

18 Mar 2026 by

In the treatment of patients with muscle-invasive bladder cancer (MIBC), a perioperative regimen of the antibody–drug conjugate sacituzumab govitecan plus pembrolizumab yields a promising clinical complete response rate without eliciting grade ≥4 adverse events (AEs), allowing bladder preservation without further therapy in some patients, according to the phase II SURE-02 trial.

Bladder-sparing regimen for MIBC shows promising antitumour activity

18 Mar 2026

Enfortumab vedotin plus pembrolizumab extends survival in MIBC

17 Mar 2026 by

In patients with muscle-invasive bladder cancer (MIBC) eligible for cisplatin-based chemotherapy, neoadjuvant and adjuvant enfortumab vedotin (EV) plus pembrolizumab elicits improvements in event-free survival (EFS), overall survival (OS), and pathological complete response (pCR) rate relative to neoadjuvant gemcitabine plus cisplatin, according to the phase III KEYNOTE-B15 study.

Enfortumab vedotin plus pembrolizumab extends survival in MIBC

17 Mar 2026

Pembrolizumab-belzutifan combo improves disease-free survival in clear cell renal cell carcinoma

16 Mar 2026 by

Treatment with pembrolizumab plus belzutifan results in a significant and clinically meaningful improvement in disease-free survival (DFS) compared with pembrolizumab monotherapy in patients with clear cell renal cell carcinoma (ccRCC) who are at greater risk of recurrence following nephrectomy, results from the phase III LITESPARK-022 study have shown.

Pembrolizumab-belzutifan combo improves disease-free survival in clear cell renal cell carcinoma

16 Mar 2026

No meaningful benefit to adding hormone therapy to PORT in prostate cancer

15 Mar 2026 by

The addition of hormone therapy, either short- or long-term, to postoperative radiotherapy (PORT) offers no survival advantage over PORT alone in prostate cancer, especially for men with very low pre-PORT prostate specific antigen (PSA) levels, according to the POSEIDON study.

No meaningful benefit to adding hormone therapy to PORT in prostate cancer

15 Mar 2026

Enzalutamide plus radium-223 boosts OS in mCRPC

13 Mar 2026 by

Adding enzalutamide to radium-223 significantly improves overall survival (OS) in patients with metastatic castration-resistant prostate cancer (mCRPC) compared with enzalutamide alone, according to the phase III EORTC 1333/PEACE-3 trial presented at ASCO GU 2026.